INTRODUCTION
Anthracyclines are an important class of antibiotics derived from Streptomyces. They are pigmented glycosides containing an amino sugar and a tetracyclic aglycone, an anthracyclinone [1] . Typical drugs of this class are doxorubicin (adriamycin) and daunomycin (daunorubicin), whose molecular formulae are shown in Fig. 1 , structures I and VII respectively. These drugs are widely used in the clinical treatment of human cancers but, because of their toxicity, hundreds of anthracycline derivatives have been isolated or synthesized with the aim of improving their biological properties. Although interactions with membranes [2] , Ca2+ transport [3] and sequence specificity [4] must be taken into account, the biological properties of these agents are usually attributed to their intercalative and reversible binding to DNA [5, 6] . The activity of several DNA-directed enzymes is affected by intercalating anthracyclines [7] . There is also evidence that stabilization of the DNA topoisomerase 1I-DNA complex may play a substantial role in the cytotoxicity exerted by most, but not all, anthracyclines [8] . As it has been pointed out, closely related molecules, such as doxorubicin and daunomycin, are used to cure different kinds of tumours and show similar DNAbinding geometry [9] and very similar properties towards the stabilization of the DNA topoisomerase II-DNA complex [8] . It is therefore still unclear how anthracyclines attain their wide range of biological activities, and the existence of multiple targets must be considered. Recently we have found that DNA ligases are resistant to several intercalating anthracyclines, but extremely sensitive to those bearing a free amino group on the 3'-position of the sugar [10] [11] [12] , and we have suggested that this enzyme should be considered as a potential intracellular target of anthracyclines [13] . In the present study we have analysed a group of 19 anthracycline derivatives which differ by the substitution pattern on the aglycone as well as on the sugar moiety. The study has identified some structural properties of anthracyclines which are connected with the inhibition of the DNAligase joining activity. It also shows that these properties derive from the interaction of these agents with the DNA substrate.
EXPERIMENTAL

Materials
Anthracycline derivatives, whose structure is shown in Fig. 1 Table 1 . The most striking features were: (1) the inability of 3',4'-deamino or modified amino anthracyclines to inhibit the DNA-joining activity of human DNA ligase; (2) the generalized inhibitory activity associated with molecules bearing a free amino group on the sugar moiety; (3) the strongest inhibitory activity associated with molecules possessing a 3'-amino-4'-deoxy sugar.
Comparative effects of 3'-amino-4'-deoxy-anthracyclines Six analogues with a 4'-deoxy sugar (III, IV, VIII, X, XII and XVI) were tested. The three possessing a 3'-amino-4'-deoxy-sugar carrying no other modifications (III, VIII and XII) exhibited the most potent inhibition of the joining activity of the human DNA ligase, both when compared with the 4'-hydroxy counterparts (Figs. 2a, 2b and 2c) and in absolute terms ( Table 1) . The modifications present on the aglycones, deriving from doxorubicin, daunorubicin and 4-demethoxydoxorubicin, have little influence on DNA-ligase-inhibitory potential (Table 1) . A 4'-deoxy-4'-amino-sugar analogue carrying the amino group in the 4'-epi position (XVI) with no other modification on the sugar showed very low activity (Fig. 2c) . The 3',4'-diamino-sugar anthracycline (X) showed an inhibition pattern similar to that of its 3'-amino-4'-hydroxy counterpart (VII, daunomycin), well below the values of inhibition of the 3'-deoxy-4'-aminodaunorubicin (VIII, Fig. 2b) . Substitution of the hydroxy group with an iodine atom in 3' (IV) at low doses further reduced the inhibitory capability of the analogue (Fig. 2a) .
Comparative effects of C-14 hydroxylation
The availability of other analogues allowed us to analyse the effects of other structural alterations. For example, the addition of a hydroxy group at C-14 of daunorubicin transforms it into doxorubicin, which is therefore an extremely similar molecule, Vol. 279 with almost identical properties with respect to stabilization of the DNA topoisomerase II-DNA complex and DNA-binding geometry [9] but, nevertheless, with different tumour specificity [8] . We found that doxorubicin (I) and daunorubicin (VII) differ by a factor of approx. 2.5 in their ID50 for the joining activity of human DNA ligase (Table 1 and Fig. 3a) , suggesting some positive influence of the hydroxy group in the C-14 position on the inhibitory activity. By contrast, 4-demethoxy molecules carrying these modifications at C-14 (XI, XIV) suggest a negative influence of the hydroxy group (Table 1 and Fig. 3b ). In the case of both the very active 4'-deoxy (III, VIII) and the inactive 3'-deamino-3'-hydroxy-4'-epihydroxy molecules (XII, XVII), no effects of the C-14 modification were evident.
Comparative effects of 4-methoxyanthracycines
A similar analysis is also possible for molecules differing only in the 4-demethoxy modification. Whereas doxorubicin (I) is more potent than its 4-demethoxy counterpart (XI) ( Table 1 and Fig. 4a ), daunorubicin (VII) is less potent than its 4-demethoxy counterpart (XIV) ( Table 1 and Fig. 4d) . Again, no significant differences were found between the two very active 4'-deoxy (HI, XII) and between the two inactive 3'-deamino-3'-hydroxy-4'-epihydroxy (V, XIII) molecules. itself in the self-catalysed, DNA-independent, reaction with ATP[35S] [16] (Fig. 6) . Although most of the test anthracyclines were found to be inactive in this assay, the most active anthracycline derivative of this group is the 3'-deamino-4'-deoxy-4'-epiamino-4-demethoxydaunorubicin (XVI). Also, the second most potent anthracycline derivative is a 4'-amino sugar analogue carrying a hydroxy group in the 3' position of the sugar associated with the doxorubicin aglycone.
DISCUSSION
The results described here, of DNA-joining inhibition, were obtained with a substrate of poly[d(A-T)], whose nucleotide sequence has been reported to be recognized with medium strength by daunomycin [17] as substrate. Therefore, keeping in mind that some differences might, however, exist between poly[d(A-T)] and DNA recognition by the different anthracycline derivatives studied in the present work, we believe that our results can be readily extrapolated to DNA. And, indeed, some derivatives have already given similar results in a reliable, but more difficult, DNA-circularization assay [10] . The present results well confirm previously described, more limited, observations on the inhibition of both bacteriophage T4 and human DNA ligase by amino-sugar anthracyclines [10, 12] . The introduction in the test group of anthracyclines carrying deoxyaminosugar gave rise to the discovery of a new class of human DNA ligase inhibitors (III, VIII and XII) more powerful than that previously described for bacteriophage-T4 DNA ligase (I, II, III and XIV). The slight influence of modifications on the aglycone residue of most active molecules stresses even more the role played by the 3'-amino group on the sugar during the inhibition of the human DNA ligase. These anthracycline derivatives are very poor inhibitors of the first step of the DNA-joining reaction: the DNA-independent adenylation of the human ligase. Doxorubicin (I) had already been reported to be inactive against the same reaction catalysed by the bacteriophage T4 DNA ligase [11] , and the present results strengthen the conclusion that, in the case of anthracyclines also, inhibition of DNA ligase activity is obtained via interaction with the substrate, DNA, as already proposed for other DNA-binding drugs such as ethidium bromide and 4',6-diamidino-2-phenylindole [11] . Therefore, just as in the case of topoisomerase IItargeted [8] and bacteriophage-T4 DNA ligase-inhibiting anthracyclines [10] , DNA intercalation is required, but not in itself sufficient, for the activity against human replicative DNA ligase.
Crystallographic studies indicate that, during DNA intercalation, the anthracycline aglycone lies between basepairs per- 6 4 pendicular to the axis of the double helix [9] . At the same time the sugar residue hangs into the minor groove with the 3'-amino group well exposed into the same groove. Our findings appear to confer to the position occupied by the positively charged 3'-amino group a strategic role for the inactivation of the DNA ligase. Therefore our observations go well beyond the reported biological inactivity of the aglycone chromophore without an amino sugar [1] . It is still unclear what kind of interactions occur between the 'hanging' amino group and the enzyme. However, the interaction must be very specific, since it does not seem to depend on simple spatial occupancy or charge. In fact anthracyclines with the amino group modified in a cyanomorpholine residue or substituted with a hydroxy group are inactive, whereas a 3',4'-diamino-sugar anthracycline is less active than anthracyclines with a single amino group at 3'. No information has so far been obtained for DNA ligase inhibition by 9'-deoxy molecules. The importance of these molecules relies on the observed reduction of cytotoxicity of anthracyclines carrying this modification [18] .
However, small modifications in positions 4 and 14 of the aglycone do not significantly alter the strong inhibition mediated by the three very active 3'-amino-4'-deoxyanthracyclines. By contrast, the same modifications introduced in 3'-amino-4'-hydroxy molecules result in significant variation of the inhibitory response. Similar variations have not been detected in the case of the instability of the DNA topoisomerase II-DNA complexes [8] . Therefore the observed variation of the inhibitory response in the case of replicative DNA ligase activity acquires special significance. In fact it is known that closely related anthracyclines are commonly used to cure different tumours [1] . A working hypothesis can therefore be made based on the existence of different levels of multiple enzymic targets for anthracyclines in 
